Mode
Text Size
Log in / Sign up

Left-Sided Breast Cancer

Part of Hormone Receptor-Positive Breast Cancer

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Hormone Receptor-Positive Breast Cancer

Related studies from across the Hormone Receptor-Positive Breast Cancer family.

RPN1 overexpression promotes immune evasion and treatment resistance in multiple malignancies including hepatocellular carcinoma
Drug Pipeline Sys. Review
RPN1 overexpression promotes immune evasion and treatment resistance in multiple malignancies including hepatocellular carcinoma RPN1 Protein Linked to Worse Outcomes in Several Cancers
This systematic review examines the role of RPN1 in glioma, hepatocellular carcinoma, sarcoma, and triple-negative breast cancer. The author…
High levels of the RPN1 protein are linked to aggressive cancer features and help tumors hide from the body's immune system.
ICIs Boost pCR in Early Triple-Negative Breast Cancer
Oncology Meta-analysis
ICIs Boost pCR in Early Triple-Negative Breast Cancer Immune drugs combined with chemotherapy improve results for triple-negative breast cancer
Adding immune checkpoint inhibitors to chemotherapy improves pathological complete response in early triple-negative breast cancer, with PD-…
Adding immune checkpoint inhibitors to chemotherapy significantly increases the chance of clearing cancer cells in triple-negative breast ca…
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
OB/GYN & Women's Health Sys. Review
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC New data shows specific drug combinations improve triple-negative breast cancer outcomes
This network meta-analysis of 7,683 patients with early-stage triple-negative breast cancer (TNBC) evaluated various neoadjuvant treatment r…
New data shows that adding specific drugs like pembrolizumab or bevacizumab to standard chemotherapy can improve response rates for early-st…
Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
Oncology Meta-analysis
Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC Targeted therapy plus chemotherapy improves response in triple-negative breast cancer
This systematic review and meta-analysis of 523 patients found that adding targeted therapy to chemotherapy for advanced triple-negative bre…
Adding targeted therapy to chemotherapy may improve how tumors respond in patients with advanced triple-negative breast cancer.
Adjuvant CDK4/6 inhibitors improve invasive Disease-Free Survival regardless of patient menopausal status
Oncology Meta-analysis
Adjuvant CDK4/6 inhibitors improve invasive Disease-Free Survival regardless of patient menopausal status CDK4/6 inhibitors show consistent results for both pre and postmenopausal women
This meta-analysis of 17,748 patients with HR+ and HER2-negative early breast cancer found that adjuvant CDK4/6 inhibitors improved invasive…
New data suggests that a specific type of breast cancer treatment works effectively regardless of whether a patient has reached menopause.
Neoadjuvant immune checkpoint inhibitors plus chemotherapy increase pathological complete response in early-stage triple-negative breast cancer
Allergy & Immunology Meta-analysis
Neoadjuvant immune checkpoint inhibitors plus chemotherapy increase pathological complete response in early-stage triple-negative breast cancer Immune checkpoint inhibitors improve response in triple-negative breast cancer
This meta-analysis of 3,377 patients found that neoadjuvant immune checkpoint inhibitors combined with chemotherapy significantly increased …
Adding immune checkpoint inhibitors to chemotherapy helps more patients with early-stage triple-negative breast cancer achieve a complete re…
Chemokine networks regulate triple-negative breast cancer tumor microenvironment but clinical translation remains limited
Oncology Sys. Review
Chemokine networks regulate triple-negative breast cancer tumor microenvironment but clinical translation remains limited Chemokine Targets Show Promise in Lab but Face Clinical Hurdles
This systematic review examines the role of chemokine networks and targeted interventions in the triple-negative breast cancer immune microe…
New research highlights the role of chemokine networks in breast cancer, showing strong results in labs despite challenges in current clinic…
Datopotamab deruxtecan improves progression-free survival to 10.8 months versus 5.6 months in TNBC
OB/GYN & Women's Health RCT
Datopotamab deruxtecan improves progression-free survival to 10.8 months versus 5.6 months in TNBC Trial shows datopotamab deruxtecan improves survival in triple-negative breast cancer
This Phase III randomized controlled trial of 644 patients with untreated, locally recurrent inoperable or metastatic triple-negative breast…
A new trial shows that datopotamab deruxtecan may extend progression-free and overall survival for patients with advanced triple-negative br…
Adenomatoid tumor should be considered in the differential diagnosis for testicular lesions in patients with cryptorchidism
Oncology Sys. Review
Adenomatoid tumor should be considered in the differential diagnosis for testicular lesions in patients with cryptorchidism Testicular Adenomatoid Tumor Linked to History of Cryptorchidism
This case report and literature review describes a 58-year-old man with cryptorchidism, male breast cancer, and thymic B2 thymoma who presen…
A new case report highlights a link between undescended testes and certain benign testicular tumors, helping doctors better identify similar…
Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
Oncology Meta-analysis
Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer Immunotherapy plus chemo improves survival in triple-negative breast cancer
This umbrella meta-analysis of 39,147 patients found that combining immune checkpoint inhibitors with chemotherapy significantly improves ov…
Adding immunotherapy to chemo helps some patients with advanced triple-negative breast cancer live longer, but side effects are more common.
Multimodal fusion and radiogenomic frameworks show promise for capturing heterogeneity in triple-negative breast cancer
Oncology Sys. Review
Multimodal fusion and radiogenomic frameworks show promise for capturing heterogeneity in triple-negative breast cancer Artificial Intelligence Shows Promise in Triple-Negative Breast Cancer Care
This narrative synthesis reviews the application of artificial intelligence across radiology, digital pathology, and multi-omics for triple-…
New research shows how artificial intelligence can help identify cancer subtypes and predict treatment responses for patients with triple-ne…
Small intestinal metastasis from triple-negative breast cancer can mimic lymphoma on imaging
Oncology Sys. Review
Small intestinal metastasis from triple-negative breast cancer can mimic lymphoma on imaging Case report: Breast cancer spread to small intestine mimics lymphoma
This case report with literature review describes a patient with triple-negative breast cancer who developed small intestinal metastasis pre…
A breast cancer survivor's anemia was caused by a rare small intestine metastasis that looked like lymphoma on scans.